Janet Woodcock, AP Images

FDA’s Wood­cock weighs in on role of NIH in drug de­vel­op­ment

The FDA Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) di­rec­tor Janet Wood­cock said Wednes­day that while the NIH has been in­stru­men­tal to drug dis­cov­ery and de­vel­op­ment, she does not think the NIH or aca­d­e­mics should be in the busi­ness of de­vel­op­ing new phar­ma­ceu­ti­cals.

The com­ments came as part of the first day of a two-day meet­ing at the Na­tion­al Acad­e­mies of Sci­ences, En­gi­neer­ing and Med­i­cine in Wash­ing­ton, DC, on the role of the NIH in drug de­vel­op­ment in­no­va­tion and the im­pact on pa­tient ac­cess.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.